{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:43:29Z","timestamp":1781678609450,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R21 DA044744"],"award-info":[{"award-number":["R21 DA044744"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K12 DA041449"],"award-info":[{"award-number":["K12 DA041449"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Potential differences in buprenorphine treatment outcomes across various treatment settings are poorly characterized in multi-state administrative data. We thus evaluated the association of opioid use disorder (OUD) treatment setting and insurance type with risk of buprenorphine discontinuation among commercial insurance and Medicaid enrollees initiated on buprenorphine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this observational, retrospective cohort study using the Merative MarketScan databases (2006\u20132016), we analyzed buprenorphine retention in 58,200 US adults with OUD. Predictor variables included insurance status (Medicaid vs commercial) and treatment setting, operationalized as substance use disorder (SUD) specialty treatment facility versus outpatient primary care physicians (PCPs) versus outpatient psychiatry, ascertained by linking physician visit codes to buprenorphine prescriptions. Treatment setting was inferred based on timing of prescriber visit claims preceding prescription fills. We estimated time to buprenorphine discontinuation using multivariable cox regression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among enrollees with OUD receiving buprenorphine, 26,168 (45.0%) had prescriptions from SUD facilities without outpatient buprenorphine treatment, with the remaining treated by outpatient PCPs (n\u2009=\u200923,899, 41.1%) and psychiatrists (n\u2009=\u20098133, 13.9%). Overall, 50.6% and 73.3% discontinued treatment at 180 and 365\u00a0days respectively. Buprenorphine discontinuation was higher among enrollees receiving prescriptions from SUD facilities (aHR\u2009=\u20091.03[1.01\u20131.06]) and PCPs (aHR\u2009=\u20091.07[1.05\u20131.10]). Medicaid enrollees had lower buprenorphine retention than those with commercial insurance, particularly those receiving buprenorphine from SUD facilities and PCPs (aHR\u2009=\u20091.24[1.20\u20131.29] and aHR\u2009=\u20091.39[1.34\u20131.45] respectively, relative to comparator group of commercial insurance enrollees receiving buprenorphine from outpatient psychiatry).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Buprenorphine discontinuation is high across outpatient PCP, psychiatry, and SUD treatment facility settings, with potentially lower treatment retention among Medicaid enrollees receiving care from SUD facilities and PCPs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-024-00450-0","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T06:01:42Z","timestamp":1710568902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6595-695X","authenticated-orcid":false,"given":"Kevin Y.","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex K.","family":"Gertner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly F.","family":"Greenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Robin","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Grucza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"key":"450_CR1","doi-asserted-by":"publisher","DOI":"10.31478\/202004b","author":"BK Madras","year":"2020","unstructured":"Madras BK, Ahmad NJ, Wen J, Sharfstein J. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. National academy of medicine 2020. The prevention, treatment, and recovery working group of the action collaborative on countering the U.S. Opioid Epidemic. NAM Perspect. 2020. https:\/\/doi.org\/10.31478\/202004b.","journal-title":"NAM Perspect"},{"issue":"5","key":"450_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.11363","volume":"5","author":"KY Xu","year":"2022","unstructured":"Xu KY, Mintz CM, Presnall N, Bierut LJ, Grucza RA. Comparative effectiveness associated with buprenorphine and naltrexone in opioid use disorder and cooccurring polysubstance use. Jama Netw Open. 2022;5(5): e2211363.","journal-title":"Jama Netw Open."},{"issue":"2","key":"450_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. Jama Netw Open. 2020;3(2): e1920622.","journal-title":"Jama Netw Open."},{"issue":"6 Suppl 3","key":"450_CR4","doi-asserted-by":"publisher","first-page":"S230","DOI":"10.1016\/j.amepre.2017.12.022","volume":"54","author":"RL Haffajee","year":"2018","unstructured":"Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54(6 Suppl 3):S230\u201342.","journal-title":"Am J Prev Med"},{"issue":"2","key":"450_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jsat.2010.05.004","volume":"39","author":"CL Arfken","year":"2010","unstructured":"Arfken CL, Johanson CE, di Menza S, Schuster CR. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J Subst Abuse Treat. 2010;39(2):96\u2013104.","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"450_CR6","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1377\/hlthaff.2019.01559","volume":"39","author":"AK Gertner","year":"2020","unstructured":"Gertner AK, Robertson AG, Powell BJ, Jones H, Silberman P, Domino ME. Primary care providers and specialists deliver comparable buprenorphine treatment quality. Health Aff (Millwood). 2020;39(8):1395\u2013404.","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"450_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11414-018-9629-4","volume":"46","author":"HK Knudsen","year":"2019","unstructured":"Knudsen HK, Studts JL. Physicians as mediators of health policy: acceptance of medicaid in the context of buprenorphine treatment. J Behav Health Ser R. 2019;46(1):151\u201363.","journal-title":"J Behav Health Ser R"},{"issue":"7","key":"450_CR8","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1176\/appi.ps.201700363","volume":"69","author":"A Manhapra","year":"2018","unstructured":"Manhapra A, Agbese E, Leslie DL, Rosenheck RA. Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults. Psychiat Serv. 2018;69(7):768\u201376.","journal-title":"Psychiat Serv"},{"issue":"5","key":"450_CR9","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1377\/hlthaff.2022.01513","volume":"42","author":"B Andraka-Christou","year":"2023","unstructured":"Andraka-Christou B, Simon KI, Bradford WD, Nguyen T. Buprenorphine treatment for opioid use disorder: comparison of insurance restrictions, 2017\u201321. Health Aff. 2023;42(5):658\u201364.","journal-title":"Health Aff"},{"issue":"6","key":"450_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.18487","volume":"6","author":"MJ Nguemeni Tiako","year":"2023","unstructured":"Nguemeni Tiako MJ, Dolan A, Abrams M, Oyekanmi K, Meisel Z, Aronowitz SV. Thematic analysis of state medicaid buprenorphine prior authorization requirements. JAMA Netw Open. 2023;6(6): e2318487.","journal-title":"JAMA Netw Open"},{"key":"450_CR11","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20081174","author":"KY Xu","year":"2021","unstructured":"Xu KY, Borodovsky JT, Presnall N, Mintz CM, Hartz SM, Bierut LJ, et al. Association between benzodiazepine or Z-drug prescriptions and drug-related poisonings among patients receiving buprenorphine maintenance: a case-crossover analysis. Am J Psychiatry. 2021. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20081174.","journal-title":"Am J Psychiatry."},{"issue":"1","key":"450_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13722-023-00405-x","volume":"18","author":"JF Scherrer","year":"2023","unstructured":"Scherrer JF, Sullivan MD, LaRochelle MR, Grucza R. Validating opioid use disorder diagnoses in administrative data: a commentary on existing evidence and future directions. Addict Sci Clin Pract. 2023;18(1):49.","journal-title":"Addict Sci Clin Pract"},{"key":"450_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s11469-022-00985-w","author":"HR Dong","year":"2022","unstructured":"Dong HR, Stringfellow EJ, Russell WA, Bearnot B, Jalali MS. Impact of alternative ways to operationalize buprenorphine treatment duration on understanding continuity of care for opioid use disorder. Int J Ment Health Ad. 2022. https:\/\/doi.org\/10.1007\/s11469-022-00985-w.","journal-title":"Int J Ment Health Ad."},{"key":"450_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jsat.2019.07.010","volume":"105","author":"A Meinhofer","year":"2019","unstructured":"Meinhofer A, Williams AR, Johnson P, Schackman BR, Bao YH. Prescribing decisions at buprenorphine treatment initiation: do they matter for treatment discontinuation and adverse opioid-related events? J Subst Abuse Treat. 2019;105:37\u201343.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"450_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","volume":"177","author":"AR Williams","year":"2020","unstructured":"Williams AR, Samples H, Crystal S, Olfson M. Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. Am J Psychiat. 2020;177(2):117\u201324.","journal-title":"Am J Psychiat"},{"key":"450_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2023.100195","volume":"9","author":"KY Xu","year":"2023","unstructured":"Xu KY, Huang V, Williams AR, Martin CE, Bazazi AR, Grucza RA. Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: an analysis of insurance claims. Drug Alcohol Depend Rep. 2023;9: 100195.","journal-title":"Drug Alcohol Depend Rep"},{"key":"450_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k5092","volume":"364","author":"KP Chua","year":"2019","unstructured":"Chua KP, Fischer MA, Linder JA. Appropriateness of outpatient antibiotic prescribing among privately insured US patients: ICD-10-CM based cross sectional study. BMJ. 2019;364: k5092.","journal-title":"BMJ."},{"key":"450_CR18","doi-asserted-by":"publisher","first-page":"108140","DOI":"10.1016\/j.jsat.2020.108140","volume":"119","author":"A Jakubowski","year":"2020","unstructured":"Jakubowski A, Lu T, DiRenno F, Jadow B, Giovanniello A, Nahvi S, et al. Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program. J Subst Abuse Treat. 2020;119:108140.","journal-title":"J Subst Abuse Treat."},{"issue":"2","key":"450_CR19","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamapediatrics.2020.5035","volume":"175","author":"JK Lim","year":"2021","unstructured":"Lim JK, Earlywine JJ, Bagley SM, Marshall BDL, Hadland SE. Polysubstance involvement in opioid overdose deaths in adolescents and young adults, 1999\u20132018. JAMA Pediatr. 2021;175(2):194\u20136.","journal-title":"JAMA Pediatr"},{"issue":"1","key":"450_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/ADM.0000000000000823","volume":"16","author":"JN Park","year":"2022","unstructured":"Park JN, Schneider KE, Fowler D, Sherman SG, Mojtabai R, Nestadt PS. Polysubstance overdose deaths in the fentanyl era: a latent class analysis. J Addict Med. 2022;16(1):49\u201355.","journal-title":"J Addict Med"},{"issue":"2","key":"450_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s11606-020-06448-z","volume":"37","author":"AJ Kennedy","year":"2022","unstructured":"Kennedy AJ, Wessel CB, Levine R, Downer K, Raymond M, Osakue D, et al. Factors associated with long-term retention in buprenorphine-based addiction treatment programs: a systematic review. J Gen Intern Med. 2022;37(2):332\u201340.","journal-title":"J Gen Intern Med"},{"issue":"9","key":"450_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.34540","volume":"6","author":"LC Chambers","year":"2023","unstructured":"Chambers LC, Hallowell BD, Zullo AR, Paiva TJ, Berk J, Gaither R, et al. Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl. Jama Netw Open. 2023;6(9): e2334540.","journal-title":"Jama Netw Open."},{"issue":"3","key":"450_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2105\/AJPH.2018.304899","volume":"109","author":"A Van Zee","year":"2019","unstructured":"Van Zee A, Fiellin DA. Proliferation of cash-only buprenorphine treatment clinics: a threat to the nation\u2019s response to the opioid crisis. Am J Public Health. 2019;109(3):393\u20134.","journal-title":"Am J Public Health"},{"issue":"6","key":"450_CR24","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1176\/appi.ps.202000491","volume":"72","author":"M Olfson","year":"2021","unstructured":"Olfson M, Zhang V, King M, Mojtabai R. Changes in buprenorphine treatment after medicaid expansion. Psychiatr Serv. 2021;72(6):633\u201340.","journal-title":"Psychiatr Serv"},{"issue":"2","key":"450_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10488-012-0449-1","volume":"41","author":"MP McGovern","year":"2014","unstructured":"McGovern MP, Lambert-Harris C, Gotham HJ, Claus RE, Xie HY. Dual diagnosis capability in mental health and addiction treatment services: an assessment of programs across multiple state systems. Adm Policy Ment Hlth. 2014;41(2):205\u201314.","journal-title":"Adm Policy Ment Hlth"},{"key":"450_CR26","volume-title":"Substance abuse and mental health services administration, dual diagnosis capability in addiction treatment toolkit version 4.0","author":"Substance Abuse and Mental Health Services Administration","year":"2011","unstructured":"Substance Abuse and Mental Health Services Administration. Substance abuse and mental health services administration, dual diagnosis capability in addiction treatment toolkit version 4.0. Rockville: Substance Abuse and Mental Health Services Administration; 2011."},{"key":"450_CR27","doi-asserted-by":"publisher","first-page":"103715","DOI":"10.1016\/j.drugpo.2022.103715","volume":"105","author":"AK Gertner","year":"2022","unstructured":"Gertner AK, Clare HM, Powell BJ, Gilbert AR, Jones HE, Silberman P, et al. A mixed methods study of provider factors in buprenorphine treatment retention. Int J Drug Policy. 2022;105:103715.","journal-title":"Int J Drug Policy."},{"issue":"1\u20133","key":"450_CR28","first-page":"49","volume":"18","author":"AL McNary","year":"2021","unstructured":"McNary AL. Myths and misconceptions: terminating treatment. Innov Clin Neurosci. 2021;18(1\u20133):49\u201351.","journal-title":"Innov Clin Neurosci"},{"issue":"10","key":"450_CR29","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1176\/ps.2009.60.10.1323","volume":"60","author":"KC Thomas","year":"2009","unstructured":"Thomas KC, Ellis AR, Konrad TR, Holzer CE, Morrissey JP. County-level estimates of mental health professional shortage in the United States. Psychiat Serv. 2009;60(10):1323\u20138.","journal-title":"Psychiat Serv"},{"issue":"8","key":"450_CR30","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.jpsychires.2011.03.006","volume":"45","author":"CP McLean","year":"2011","unstructured":"McLean CP, Asnaani A, Litz BT, Hofmann SG. Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. J Psychiatr Res. 2011;45(8):1027\u201335.","journal-title":"J Psychiatr Res"},{"issue":"1","key":"450_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1176\/appi.prcp.20190051","volume":"3","author":"C Barbosa-Leiker","year":"2021","unstructured":"Barbosa-Leiker C, Campbell ANC, McHugh RK, Guille C, Greenfield SF. Opioid use disorder in women and the implications for treatment. Psychiatr Res Clin Pract. 2021;3(1):3\u201311.","journal-title":"Psychiatr Res Clin Pract"},{"issue":"1","key":"450_CR32","doi-asserted-by":"publisher","first-page":"S626","DOI":"10.1016\/j.ajog.2019.11.1022","volume":"222","author":"MJ Stout","year":"2020","unstructured":"Stout MJ, Bedrick B, O\u2019Donnell C, Hernandez J, Carter EB, Kelly J. Access to buprenorphine in pregnancy: minimizing barriers for patients. Am J Obstet Gynecol. 2020;222(1):S626\u20137.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"450_CR33","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/AOG.0000000000005117","volume":"141","author":"KY Xu","year":"2023","unstructured":"Xu KY, Jones HE, Schiff DM, Martin CE, Kelly JC, Carter EB, et al. Initiation and treatment discontinuation of medications for opioid use disorder in pregnant people compared with nonpregnant people. Obstet Gynecol. 2023;141(4):845\u201353.","journal-title":"Obstet Gynecol"},{"key":"450_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-023-08306-0","author":"KY Xu","year":"2023","unstructured":"Xu KY, Schiff DM, Jones HE, Martin CE, Kelly JC, Bierut LJ, et al. Racial and ethnic inequities in buprenorphine and methadone utilization among reproductive-age women with opioid use disorder: an analysis of multi-state medicaid claims in the USA. J Gen Intern Med. 2023. https:\/\/doi.org\/10.1007\/s11606-023-08306-0.","journal-title":"J Gen Intern Med."},{"issue":"4","key":"450_CR35","doi-asserted-by":"publisher","first-page":"424.e1","DOI":"10.1016\/j.ajog.2021.04.210","volume":"225","author":"DM Schiff","year":"2021","unstructured":"Schiff DM, Nielsen TC, Hoeppner BB, Terplan M, Hadland SE, Bernson D, et al. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder. Am J Obstet Gynecol. 2021;225(4):424.e1.","journal-title":"Am J Obstet Gynecol."},{"issue":"3","key":"450_CR36","first-page":"162","volume":"28","author":"S Greenfield","year":"2019","unstructured":"Greenfield S, Rosa C, Barbosa-Leiker C, Campbell A, McHugh K, Guille C, et al. Opioid Use Disorder in Women: Evidence from the National Institute on Drug Abuse Clinical Trials Network (CTN) and the Implications for Treatment. Am J Addictn. 2019;28(3):162.","journal-title":"Am J Addictn."},{"issue":"1","key":"450_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/JAN.0000000000000160","volume":"28","author":"KS Fornili","year":"2017","unstructured":"Fornili KS, Fogger SA. Nurse practitioner prescriptive authority for buprenorphine: from DATA 2000 to CARA 2016. J Addict Nurs. 2017;28(1):43\u20138.","journal-title":"J Addict Nurs"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00450-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-024-00450-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00450-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T06:02:17Z","timestamp":1710568937000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-024-00450-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["450"],"URL":"https:\/\/doi.org\/10.1186\/s13722-024-00450-0","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,16]]},"assertion":[{"value":"9 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Grucza reported receiving grants from the NIH and Arnold Ventures LLC during the conduct of the study, consulting for Janssen Pharmaceuticals, and receiving personal fees for grant reviews from the NIH outside the submitted work.\u00a0Dr. Williams receives consulting fees, equity, and travel reimbursement from Ophelia Health Inc, a telehealth company for the treatment of OUD. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}